163 related articles for article (PubMed ID: 37869099)
1. Surgery after combination therapy with a tyrosine kinase inhibitor and anti-PD-1 antibody in sarcomatoid hepatocellular carcinoma: case report and literature review.
Liang B; Huang T; Kuang SL; Xie GY; Liu TQ; Chen YY
Front Oncol; 2023; 13():1212013. PubMed ID: 37869099
[TBL] [Abstract][Full Text] [Related]
2. Sarcomatoid hepatocellular carcinoma (SHC): a case report.
Yu Y; Zhong Y; Wang J; Wu D
World J Surg Oncol; 2017 Dec; 15(1):219. PubMed ID: 29233162
[TBL] [Abstract][Full Text] [Related]
3. Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.
Zhu XD; Huang C; Shen YH; Ji Y; Ge NL; Qu XD; Chen L; Shi WK; Li ML; Zhu JJ; Tan CJ; Tang ZY; Zhou J; Fan J; Sun HC
Liver Cancer; 2021 Jul; 10(4):320-329. PubMed ID: 34414120
[TBL] [Abstract][Full Text] [Related]
4. Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.
Xu B; Zhu XD; Shen YH; Zhu JJ; Liu J; Li ML; Tang PW; Zhou J; Fan J; Sun HC; Huang C
Front Immunol; 2022; 13():1016736. PubMed ID: 36505445
[TBL] [Abstract][Full Text] [Related]
5. Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: A case report.
Zhu SG; Li HB; Yuan ZN; Liu W; Yang Q; Cheng Y; Wang WJ; Wang GY; Li H
World J Gastrointest Oncol; 2020 Oct; 12(10):1209-1215. PubMed ID: 33133387
[TBL] [Abstract][Full Text] [Related]
6. Sarcomatoid hepatocellular carcinoma mimicking hepatic abscess: A case report.
Yang Z; Lv K; Zhao Y; Pan M; Zhang C; Wei S
Medicine (Baltimore); 2020 Sep; 99(39):e22489. PubMed ID: 32991488
[TBL] [Abstract][Full Text] [Related]
7. Concomitant early gallbladder carcinoma with primary sarcomatoid hepatocellular carcinoma: A case report.
Xue D; Zuo K; Li X; Chen H; Xu Y; Cheng Y; Chen Y
Oncol Lett; 2013 Jun; 5(6):1965-1967. PubMed ID: 23833676
[TBL] [Abstract][Full Text] [Related]
8. Sarcomatoid Intrahepatic Cholangiocarcinoma After Immunotherapy: A Case Report and Review of the Literature.
Zeng Z; Liu Y; Yu J; Xu Q; Wang Y; Zhao C; Jiang O
J Clin Transl Hepatol; 2022 Dec; 10(6):1240-1249. PubMed ID: 36381099
[TBL] [Abstract][Full Text] [Related]
9. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma.
Chen K; Luo CP; Ge DX; Wang KL; Luo Q; Li YZ; You XM; Xiang BD; Li LQ; Ma L; Zhong JH
Front Oncol; 2022; 12():946693. PubMed ID: 36276151
[TBL] [Abstract][Full Text] [Related]
10. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.
Chen Z; Chen Z; Fan W; Zou Y; Zhang Y; Shi N; Jin H
World J Surg Oncol; 2023 Jan; 21(1):29. PubMed ID: 36721173
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study.
Yi Y; Sun BY; Weng JL; Zhou C; Zhou CH; Cai MH; Zhang JY; Gao H; Sun J; Zhou J; Fan J; Ren N; Qiu SJ
Front Oncol; 2022; 12():1046584. PubMed ID: 36505772
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.
Huang J; Wang ZG; Tao QF; Yang Y; Yuan SX; Gu FM; Liu H; Pan ZY; Jiang BG; Lau WY; Zhou WP
Front Immunol; 2023; 14():1198562. PubMed ID: 37483609
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study.
Wu JY; Wu JY; Li YN; Qiu FN; Zhou SQ; Yin ZY; Chen YF; Li B; Zhou JY; Yan ML
Front Oncol; 2022; 12():985380. PubMed ID: 36212494
[TBL] [Abstract][Full Text] [Related]
15. Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma.
Sano S; Asahi Y; Kamiyama T; Kakisaka T; Orimo T; Nagatsu A; Aiyama T; Kazui K; Shomura H; Ueki S; Sakamoto Y; Shirakawa C; Kamachi H; Sugino H; Mitsuhashi T; Taketomi A
Int Cancer Conf J; 2023 Jan; 12(1):7-13. PubMed ID: 36605836
[TBL] [Abstract][Full Text] [Related]
16. Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy.
Xie QY; Liu HY; Guo ZY; Wu YP; He GL; Cai L; Pan MX; Fu SJ
Front Mol Biosci; 2021; 8():810251. PubMed ID: 35187075
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
19. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report.
Yokoo H; Takahashi H; Hagiwara M; Iwata H; Imai K; Saito Y; Matsuno N; Furukawa H
World J Hepatol; 2020 Dec; 12(12):1349-1357. PubMed ID: 33442460
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of percutaneous mitoxantrone injection, percutaneous ethanol injection, and transcatheter arterial embolization for intrahepatic hepatocellular carcinoma and adrenal metastasis.
Kiba T; Numata K; Kitamura T; Morita K; Saito S; Sekihara H
Hepatogastroenterology; 2001; 48(38):427-31. PubMed ID: 11379324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
